hit counter
Alder Biopharmaceuticals, Inc. (ALDR) Stock News Sentiment & Price - Sentifly
ALDR - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Alder Biopharmaceuticals, Inc. (ALDR)

ALDR Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ALDR Latest news
Business Wire
Neutral
Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance
2021-09-14 08:00

SAN DIEGO--(BUSINESS WIRE)-- #cancer--Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance

GlobeNewsWire
Neutral
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
2019-10-10 08:01

ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine

The Motley Fool
Positive
Here's Why Alder Biopharmaceuticals More Than Doubled in September
2019-10-07 19:32

A Denmark-based drugmaker thought the biotech was too cheap to pass up.

Zacks Investment Research
Positive
Use Rising P/E Strategy to Grab 5 Winning Stocks
2019-09-26 05:42

Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.

The Motley Fool
Positive
Here's Why Alder Biopharmaceuticals Is Rocketing Higher Today
2019-09-16 13:17

A generous buyout offer has given investors something to cheer about.

Zacks Investment Research
Positive
Alder BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
2019-09-10 10:29

Alder BioPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire
Neutral
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society
2019-09-05 16:01

- Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine -- Preclinical data also to be presented for ALD1910, Alder’s second candidate for migraine, demonstrating its binding and selectivity to pituitary adenylate cyclase-activating peptide -

GlobeNewsWire
Neutral
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2019-08-30 16:01

BOTHELL, Wash., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted an award of 11,500 restricted stock units (“RSUs”) to a new employee under Alder’s 2018 Inducement Award Plan (the “Inducement Plan”), effective August 27, 2019.

Zacks Investment Research
Positive
All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Buy
2019-07-03 09:00

Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CNBC Television
Positive
Alder BioPharmaceuticals CEO: Addressing Chronic Migraines
2019-04-08 12:13

Jim Cramer talks with Alder BioPharmaceuticals CEO Robert Azelby to hear about the development of a migraine drug that’s waiting on FDA approval and how new leadership could improve the stock.

Loading more news...